| Literature DB >> 29378664 |
Monika Wojtera1, Josee Paradis1,2, Murad Husein1,2, Anthony C Nichols1,2, John W Barrett1,2, Marina I Salvadori1,3, Julie E Strychowsky4,5.
Abstract
BACKGROUND: HPV-related head and neck cancer rates have been increasing in recent years, with the tonsils being the most commonly affected site. However, the current rate of HPV infection in the pediatric population remains poorly defined. The objective of this study was to systematically review and evaluate the prevalence and distribution of HPV in the tonsils of pediatric patients undergoing routine tonsillectomy. METHODS ANDEntities:
Keywords: HPV; Human papillomavirus; Pediatric; Tonsils
Mesh:
Year: 2018 PMID: 29378664 PMCID: PMC5789580 DOI: 10.1186/s40463-018-0255-1
Source DB: PubMed Journal: J Otolaryngol Head Neck Surg ISSN: 1916-0208
Fig. 1Flow diagram outlining search strategy
Summary of included studies
| First Study Author & Year of Publicationa | Country | # of Patients | Age Range (Years) [mean] | Prevalence of HPVa | Testing Method | Types of HPV Tested | Types of HPV Found |
|---|---|---|---|---|---|---|---|
| Cockerill, CC (2016) [ | USA | 129 | 1–12 [NR] | 0% | Biopsy + swabs + Roche Cobas Amplicor test qPCR & E6/E7 Gene-Probe Aptima HPV test | 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | None |
| Palmer, E (2014) [ | United Kingdom | 1670 | 0–18 [NR] | 0% | Biopsy + GP5+/6+ primer PCR enzyme immunoassay + PCR E6 gene targeting for HPV16 | 20 types (unspecified), 14 high-risk and 6 low-risk | None |
| Xue, XC (2014) [ | China | 42 | 3–12 [6.8] | 0% | Biopsy + MY09/11 primer qPCR | 6, 11, 16, 18, 26, 31, 33–35, 39, 40, 42–45, 51–59, 61, 66–73, 81–84 | None |
| Sun, YF (2012) [abstract] [article in Chinese] [ | China | 177 | NR[NR] | 1% | Biopsy + PCR (unspecified) | NR | 6, 11 |
| Duray, A (2011) [ | Belgium | 42 | 0–15 [NR] | 21% | Biopsy + GP5+/GP6+ primer PCR + E6/E7 type-specific qPCR for multiple HPV subtypes | 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 | 16, NR |
| Baloglu, H (2010) [ | Turkey | 165 | 5–21 [11.9] | 7% | Biopsy + MY/GP PCR + E6/E7 type-specific PCR | 6, 11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56, 58, 59, 66, 68 | 6, 11, 16, 31 |
| Soldatskiĭ, IuA (2009) [abstract] [article in Russian] [ | Russia | 8 | 2–14 [6.8] | 13% | PCR | 6, 11, 16, 18, 31, 33 | NR |
| Mammas, IN (2006) [ | Greece | 64 | 2–14 [7.1] | 9% | Biopsy + GP5+/6+ primer PCR + type-specific PCR for multiple HPV subtypes | 11, 16, 18, 33 | 16, NR |
| Sisk, J (2006) [ | USA | 50 | 3–12 [NR] | 4% | Biopsy + MY09/11 primer PCR | NR | 11 |
| Ribeiro, KM (2006) [ | Brazil | 100 | 2–13 [NR] | 0% | Biopsy + MY09/11 primer PCR | NR | None |
| Chen, R (2005) [ | Finland | 73 | 1–16 [8.3] | 8% | Biopsy + GP5+/6+ & MY09/11 primer PCR + type-specific testing | NR | 16 |
HPV human papillomavirus, NR not reported in the study or for the tonsillectomy portion
a Articles published in English unless otherwise specified
b This study only assessed high-risk HPV subtypes. This was also the only study to report that some patients had been vaccinated against HPV; 6 (4.7%) of patients had received the vaccine
Fig. 2Geographical distribution of HPV infection in pediatric tonsils. A darker shade of blue represents a higher prevalence (≥5%), while a lighter tone represents a lower prevalence (< 5%). USA – 0%17, 4%23, United Kingdom – 0%18, China - 0%19, 1%14, Belgium – 21%20, Turkey – 7%21, Russia – 13%13, Greece – 9%22, Brazil – 0%24, Finland – 8%25
Quality assessment using a version of the Newcastle-Ottawa modified for cross-sectional studies
| Author (Year) | Selection (Maximum 4 Stars) | Comparability (Maximum 2 Stars) | Exposure (Maximum 3 Stars) | Total (Maximum 9 Stars) |
|---|---|---|---|---|
| Cockerill, CC (2016) [ | ** | * | * | **** |
| Palmer, E (2014) [ | *** | * | ** | ****** |
| Xue, X-C (2014) [ | ** | * | ** | ***** |
| Sun, YF (2012) [abstract] [article in Chinese] [ | ** | ** | * | ***** |
| Duray, A (2011) [ | ** | * | * | **** |
| Baloglu, H (2010) [ | ** | * | * | **** |
| Soldatskiĭ, IuA (2009) [abstract] [article in Russian] [ | * | * | ** | |
| Mammas, IN (2006) [ | ** | ** | ** | ****** |
| Sisk, J (2006)[ | ** | ** | ** | ****** |
| Ribeiro, KM (2006)[ | ** | * | * | **** |
| Chen, R (2005)[ | * | * | * | *** |
Fig. 3Geographical distribution of oropharyngeal cancer incidence rates per 100,000 worldwide. A darker shade of green represents rate higher than the worldwide average (≥2.0),31 while a lighter tone represents a lower rate (< 2.0%). Source: 31Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. GLOBOCAN. 2012;1.0. Available from: http://globocan.iarc.fr, accessed on 22/06/2017. USA – 3.831, United Kingdom – 3.531, China – 0.531, Belgium – 6.731, Turkey – 0.531, Russia – 2.931, Greece – 1.331, Brazil – 2.831, Finland – 2.131